Bio-Works Technologies has released its fourth-quarter and full-year financial results for 2024, revealing a period marked by significant challenges but also strategic optimism. Net sales for the fourth quarter were 2.6 MSEK, a stark decrease from 15.1 MSEK in the previous year. Despite this, the company reported a 5% increase in order intake for the year, signaling a growing demand for their products.

The operating profit for the quarter was -13.8 MSEK, slightly worse than last year's -11.8 MSEK. However, the net profit showed a minor improvement, landing at -13.2 MSEK compared to -13.3 MSEK previously. Earnings per share improved from -0.34 SEK to -0.17 SEK, indicating some financial resilience.

CEO Lone Carlbom expressed pride in the company's ability to maintain strong cost control, emphasizing the streamlining of processes as a key factor in strengthening Bio-Works' financial position. Although the company fell short of its revenue targets, an increase in resin sales volume and a growing customer base offer a silver lining.

Looking ahead, Bio-Works is optimistic about 2025, buoyed by a large order for its WorkBeads affimAb valued at 11.2 MSEK and additional orders totaling over 8 MSEK. The company plans to invest approximately 1 MSEK in production to eliminate bottlenecks and double its capacity within a year.

For investors, the strategic investments and growing order book suggest potential for future growth. While the current financials may suggest caution, the company's proactive measures and positive outlook for 2025 make it a candidate for consideration. Therefore, the recommendation is to hold the stock, awaiting further developments.